Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit.
OBJECTIVE
The mouse serves as an important model for insulin-like (IGF)-related research. However, lack of homologous mouse assays has prevented studies of the normal ontology of the murine IGF system. Therefore, we developed and validated immunoaassays for murine IGF-I, IGFBP-3 and ALS and studied levels of these analytes in mice.


METHODS
Using commercially available reagents, we developed and validated specific enzyme-linked immunosorbent assays (ELISAs) for murine IGF-I, IGFBP-3, and ALS. Levels of these analytes were measured in sera from CD-1 mice, male and female, sampled at 1, 2, 4, 8, 20 and 32 weeks of age. In addition, sera from pregnant and postpartum CD-1 mice were also studied.


RESULTS
Validation of specific ELISAs for murine IGF-I, IGFBP-3 and ALS are described; all 3 assays were highly sensitive, precise and accurate. As measured by our homologous ELISA, IGF-I levels (ng/mL, mean+/-SD) in male mice were relatively low at 1 week (53+/-8), rising sharply to peak at 8 weeks of age (636+/-48), and gradually declining thereafter, reaching 395+/-64 at 32 weeks. IGF-I levels in non-pregnant female mice peaked at 4 weeks of age (548+/-77) declined at 8 weeks (417+/-61), then recovered to plateau at 539+/-78 and 535+/-88 at 20 and 32 weeks, respectively. In male mice, trends in IGFBP-3 were similar to the patterns of IGF-I. However, in non-pregnant female mice, the IGFBP-3 levels declined relatively slowly after peaking at 4-weeks of age, unlike IGF-I levels during this period. ALS levels followed the same pattern as IGF-I in both sexes. IGF-I to IGFBP-3 molar ratios (percent) were similar between sexes, rising continuously with age: approximately 30% at 1 week, 80% at 4 weeks, 135% at 32 weeks. IGF-I was reduced in 8 week old mice in mid-pregnancy (354+/-75 vs 417+/-61 in non-pregnant 8 week females), reaching a nadir in late-term (146+/-40), and only partially recovering in the postpartum period (239+/-23). IGFBP-3 was also lower in late-pregnancy (1245+/-100 vs 1925+/-439) and remained depressed postpartum. In contrast to IGF-I and IGFBP-3, ALS increased more than threefold in mid-pregnancy (12180+/-1641 vs 3741+/-910), followed by a 4-fold decrease in late-pregnancy (2964+/-489), recovering postpartum (6104+/-1178).


CONCLUSIONS
We report the first ontological studies of IGF-I, IGFBP-3 and ALS in mice using newly-characterized sensitive, homologous immunoassays. Our results indicate that mice have a generally similar pattern in IGF-related axis components, with low levels early in life, increasing to peak during sexual maturation and declining thereafter. Significant gender differences in non-pregnant levels and dramatic changes during pregnancy were also found. Knowledge of the normal developmental changes in the murine IGF system and accurate tools for investigations of this system are a necessary foundation for research in this field.
Hwang
David L
DL
Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1752, USA.
Lee
Phillip D K
PD
Cohen
Pinchas
P
D000818:Animals; D002352:Carrier Proteins / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D013997:Time Factors
D002352:Carrier Proteins; D006023:Glycoproteins; D018972:Insulin-Like Growth Factor Binding Protein 3; C075944:insulin-like growth factor binding protein, acid labile subunit; C519530:insulin-like growth factor-1, mouse; D007334:Insulin-Like Growth Factor I
J Endocrinol. 2000 May;165(2):271-9
10810291
J Clin Endocrinol Metab. 1995 Aug;80(8):2534-42
7543116
Endocrinology. 2001 May;142(5):1958-67
11316761
J Immunol Methods. 2001 Jun 1;252(1-2):73-82
11334967
J Clin Invest. 2002 Sep;110(6):771-81
12235108
Endocrinology. 2002 Oct;143(10):3711-4
12239079
Endocr Rev. 2002 Dec;23(6):824-54
12466191
Life Sci. 2003 May 9;72(25):2887-94
12697271
Domest Anim Endocrinol. 2003 Jul;25(1):47-59
12963098
J Bone Miner Res. 1995 Nov;10(11):1698-704
8592946
J Clin Endocrinol Metab. 1996 May;81(5):2002-5
8626873
Bone. 1997 Sep;21(3):217-23
9276086
J Endocrinol. 1998 Jul;158(1):53-9
9713326
Endocrinology. 1998 Oct;139(10):4286-92
9751511
J Clin Endocrinol Metab. 1998 Dec;83(12):4408-15
9851786
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7324-9
10377413
Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):421-39
15936977
J Endocrinol Invest. 2005;28(5 Suppl):43-6
16114275
Pediatr Endocrinol Rev. 2005 Sep;3(1):11-9
16369209
Endocrinology. 2006 Mar;147(3):1175-86
16293667
Endocrinology. 2006 May;147(5):2109-11
16617154
J Endocrinol. 2006 May;189(2):289-99
16648296
J Endocrinol. 2006 Jun;189(3):583-93
16731789
Acta Obstet Gynecol Scand. 2006;85(8):900-5
16862465
Endocrinology. 2003 Nov;144(11):5058-64
12959969
Ann Clin Biochem. 2004 May;41(Pt 3):220-6
15117436
Comp Biochem Physiol A Comp Physiol. 1989;92(4):565-9
2566421
J Clin Endocrinol Metab. 1990 Oct;71(4):806-16
1698200
Endocrinology. 1990 Nov;127(5):2270-80
1699743
Biochem Soc Trans. 1990 Dec;18(6):1268
2088909
J Endocrinol. 1993 Jan;136(1):91-104
7679139
J Endocrinol. 1993 Mar;136(3):479-89
7682593
J Endocrinol. 1993 Oct;139(1):89-95
8254297
Clin Endocrinol (Oxf). 1994 Jul;41(1):85-93
7519529
Endocr J. 1993 Aug;40(4):461-5
7920900
J Clin Endocrinol Metab. 1994 Dec;79(6):1883-6
7527417
Endocrinology. 2000 Jul;141(7):2608-13
10875265